Introduction 51
Neisseria meningitidis is a Gram negative bacterium frequently encountered in human 52 nasopharynx but it is also the causative agent of invasive meningococcal disease (IMD) that 53 provokes mainly septicemia and meningitis. Neisseria meningitidis remains susceptible to 54 beta-lactams, the antibiotics of choice in the treatment of IMD (1). Resistance to beta-lactams 55 in meningococci is extremely rare, but reduced susceptibility has been described to penicillin 56 G and to amoxicillin (intermediate isolates, Pen I ). However, neither resistance nor reduced 57 susceptibility to cephalosporin of third generation has been detected so far (2). The 58 proportions of Pen I isolates differ worldwide and are increasing in several countries and can 59 reach >30% of total meningococcal isolates (3-7). 60
We have previously shown direct correlation between the polymorphism of penA gene 61 encoding the penicillin binding protein 2 (PBP2) and the Pen I phenotype. This phenotype 62 seems to result from the reduced affinity of penicillin G and amoxicillin to PBP2 as well as to 63 modification of peptidoglycan structure in Pen I isolates with increased pentapeptide-64 containing muropeptides (8). Horizontal interspecies DNA exchanges in the genus Neisseria 65 are suggested to drive the polymorphism of penA (7). Antibiotic susceptibility testing (AST) 66 is mandatory for beta-lactam antibiotics and requires reliable breakpoints to inform decision 67 making in patient treatment. 68
In order to consistently define breakpoints, sequencing of penA from a large collection of 69 isolates allowed linking wild-type alleles of penA to low minimal inhibitory concentration 70 (MIC) for penicillin G (<0.125 mg/L)(7). This defined the epidemiological cut off values for 71 susceptibility to penicillin G of MIC to be lower than 0.125 mg/L and <0.250 mg/L for 72 amoxicillin (7). It divided the meningococcal population into one part containing isolates 73 harboring wild-type alleles of penA and another part comprising isolates showing highly 74 diverse penA alleles and MICs of ≥0.125 mg/L and 0.250 mg/L for penicillin G and 75 4 amoxicillin, respectively (7). The value of MIC<0.125 mg/L was preferred to define the 76 susceptibility to penicillin G as it allows to fill the important rule to not split wild-type MIC 77 distribution (9) as isolates with wild type penA showed MIC of 0.094 mg/L(7 were of serogroup C and belonged to the clonal complex . They harbored 111 respectively the penA alleles penA3 and penA9 corresponding to a wild-type and a modified 112 alleles respectively. MIC of penicillin G was determined as previously recommended using 113
Etest with Mueller-Hinton agar supplemented with sheep blood (11) and were 0.064 mg/L 114 and 0.5 mg/L respectively. MICs of amoxicillin were 0.125 and 1.5 mg/L respectively. 115
Bioluminescent variants of both isolates were constructed by transformation with the 116 recombinant plasmid pDG34, which carries the bioluminescent luxCDABE operon under the 117 control of the porB promoter (12) and named LNP24198lux and 27704lux. Both strains were 118 checked for their MICs of penicillin G, and for amoxicillin and their penA alleles verified by 119 sequencing, showing that they were identical to the parent isolates. Both strains grew 120 similarly on meningococcal growth medium. 121
Mice infection and dynamic live imaging studies 122
We took advantage from the availability of an animal model to study N. meningitidis 123 infection, the transgenic mice expressing the human transferrin, since an iron source is 124 required for meningococcal growth (13). We have recently developed another animal model, 125 6 a transgenic mice expressing the human factor H (fH) that allowed binding of this negative 126 regulator of complement pathway on bacterial surface and hence allowing meningococci to 127 escape complement-mediated lysis (14). The two types of mice were crossed to generate 128 transgenic mice expressing both human transferrin and human fH that we used in infection 129 experiments using bioluminescent meningococcal strains with different MIC to penicillin G 130 and amoxicillin. Mice were in-house bred and were kept in a biosafety containment facility, in 131 filter-topped cages with sterile litter, water and food, according to institutional guidelines. only injected with saline as control. Interleukin-6 (IL-6) levels were also assayed in blood at 141 the end point (8 h) as previously described (15). As similar results were obtained from both 142 experiments with penicillin G and amoxicillin, IL-6 was tested for mice experiment treated 143 with amoxicillin. 144
Bacterial infection images were acquired after 0.5 h, 3 h, 6 h and 8 h of infection using an 145 IVIS 100 system (Xenogen Corp., Alameda, CA) as previously described (13 the two other doses, the signal only decreased after 8 h of infection (5 h after treatment). In 167 the untreated mice, signal continued to increase in all time points (Fig.1A) . For mice infected 168 with the strain LNP27704lux (MIC penicillin 0.5 mg/L and amoxicillin 1.5 mg/L), the 169 bioluminescent signal decreased only in mice treated with the highest dose (200 mg/kg) while 170 signal continued to increase in mice treated with 50 mg/kg and 100 mg/kg and did not differ 171 from the signal observed in untreated mice (Fig.1B) . 172
Linear regression analysis confirmed the significant decrease of bacterial viability for the 173 strain LNP24198lux in amoxicillin-treated mice in a dose-dependent manner. Negative slopes 174 were also significantly different from the slope of untreated mice (P<0.01 and r 2 of 0.38 and 175 0.85 respectively for 100 mg/kg and 200 mg/kg doses) ( Fig. 1A; 1B) . However, for the dose 176 of 50 mg/kg, the slope was not significantly different from zero (P=0.77 and r 2 =0.007) 177 suggesting bacteriostasic effect ( Fig.1A; 1B) . 178
For the strain LNP27704lux, only the 200 mg/kg dose resulted in a negative slope that 179 differed significantly from that observed with untreated mice and from the other doses of 180 amoxicillin-treated mice (P<0.001 and r 2 =0.59). For the strain LNP27704lux treated with the 181 two other doses (50 mg/kg and 100 mg/kg) the slopes were positive and similar to those of 182 untreated mice suggesting bacterial growth ( Fig. 1A; 1B) . For the 200 mg/kg-treated mice, 183 the r 2 values for the strain LNP27704lux was lower than that for strain LNP24198lux (0.59 184 versus 0.85 respectively) suggesting slower clearance of the former strain. 185
We also performed similar experiments using penicillin G with (doses of 60,000 units/kg; 186 125,000 units/kg and 250,000 units/kg). Mice were infected i.p. by the strain LNP27704 187 (MIC penicillin 0.5mg/L and amoxicillin 1.5 mg/L) and after 3 h of infection, three groups of 188 (Fig. 1C) . also contains the isolates with altered penA alleles that all shared the same altered residues (7). 255
Isolates with MICs >0.25 mg/ml and ≤ 1mg/ml may not be considered as Pen R isolates. 256
Indeed, the drug effect, in vivo, is subjective to bacterial growth rate but is also dependant on 257 host defense mechanisms. These latter aspects are not directly considered by the conventional 258 PK/PD model but can be addressed using relevant animal models as described in this work. 259 IL-6 is considered to be an important mediator of acute inflammatory responses to bacterial 260 infection (23). After 8 h of infection, the levels of IL-6 increased in mice infected by both 261 isolates and were higher in mice infected by the susceptible strain (LNP24198lux) than in 262 mice infected by the resistant isolate (LNP27704lux). This is in agreement with our previous 263 study that meningococcal isolates with modified PBP2 showed significant lower induction of 264 the inflammatory response (15). The mice treated with the higher dose did not show any 265 detectable IL-6. The trends of IL-6 levels in amoxicillin treated groups followed the 266 microbiological results. Our data are consistent with previous reports suggesting that 
